Background:Psoriasis is a chronic inflammatory skin disease,affecting about 0.6%of the Chinese population.Many patients are not well controlled by conventional treatments,thus there is need for new treatment regimens....Background:Psoriasis is a chronic inflammatory skin disease,affecting about 0.6%of the Chinese population.Many patients are not well controlled by conventional treatments,thus there is need for new treatment regimens.In this study,we assessed the efficacy and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis.Methods:This study was a 52-week,multicentre,randomized,double-blind,placebo-controlled,parallel-group,Phase 3 trial.A sub-population of study participants(≥18 years)of Chinese ethnicity were randomized to receive subcutaneous injections of 300 or 150 mg secukinumab,or placebo.The co-primary endpoints were psoriasis area severity index(PASI)75 and Investigator’s Global Assessment(IGA)0/1 at Week 12.Results:A total of 441 Chinese patients were enrolled in this study.Co-primary outcomes were achieved;300 and 150 mg secukinumab were superior to placebo as shown in the proportion of patients that achieved PASI 75(97.7%and 87.2%vs.3.7%,respectively;P<0.001),and IGA 0/1(82.3%and 69.7%vs.2.7%;P<0.001)at Week 12.Treatment efficacy was maintained until Week 52.There was no increase in overall adverse events with secukinumab relative to placebo throughout the 52-week period.Conclusion:Secukinumab is highly effective and well tolerated in Chinese patients with moderate to severe plaque psoriasis.展开更多
Background： o-galactosidase has been widely used in animal husbandry to reduce anti-nutritional factors （such as o-galactoside） in feed. Intestine-specific and substrate inducible expression of a-galactosidase woul...Background： o-galactosidase has been widely used in animal husbandry to reduce anti-nutritional factors （such as o-galactoside） in feed. Intestine-specific and substrate inducible expression of a-galactosidase would be highly beneficial for transgenic animal production. Methods： To achieve the intestine-specific and substrate inducible expression of o-galactosidase, we first identified intestine-specific promoters by comparing the transcriptional activity and tissue specificity of four intestine-specific promoters from human intestinal fatty acid binding protein, rat intestinal fatty acid binding protein, human mucin-2 and human lysozyme. We made two chimeric constructs combining the promoter and enhancer of human mucin-2, rat intestinal trefoil factor and human sucrase-isomaltase. Then a modified lac operon system was constructed to investigate the induction of o-galactosidase expression and enzyme activity by isopropyl p-D-]-thiogalactopyranoside （IPTG） and an a-galactosidase substrate, a-lactose. We declared that the research carried out on human （Zhai Yafeng） was in compliance with the Helsinki Declaration and experimental research on animals also followed internationally recognized guidelines. Results： The activity of the human mucin-2 promoter was about 2 to 3 times higher than that of other intestine-specific promoters. In the/ac operon system, the repressor significantly decreased （P 〈 0.05） luciferase activity by approximately 6.5-fold and reduced the percentage of cells expressing green fluorescent protein （GFP） by approximately 2-fold. In addition, the expression level of o-galactosidase mRNA was decreased by 6-fold and a-galactosidase activity was reduced by 8-fold. in line with our expectations, IPTG and a-lactose supplementation reversed （P 〈 O.O5） the inhibition and produced a 5-fold increase of luciferase activity, an 11-fold enhancement in the percentage of cells with GFP expression and an increase in o-galactosidase mfiNA abundance （by about 5-fold） and o-ga展开更多
Objective:To build a vomit-free ward of scientific and standardized management mode,and to evaluate its clinical effects on preventing nausea and vomiting in patients undergoing chemotherapy.Methods:A total of 200 pat...Objective:To build a vomit-free ward of scientific and standardized management mode,and to evaluate its clinical effects on preventing nausea and vomiting in patients undergoing chemotherapy.Methods:A total of 200 patients suffering from nausea and vomiting were randomly selected from the registration system,from which 120 cases were enrolled according to the inclusion and exclusion criteria.These subjects were divided into control group and observation group(60 patients in each).Both of the two groups received routine nursing care,while the treatment group subjects lived in the vomit-free wards where extra nursing interventions were applied to prevent chemotherapy-induced nausea and vomiting(CINV),with constant observation of the frequency and severity of nausea and vomiting.The outcomes of the subjects from both the groups as well as nurses’ cognition level of CINV were compared after four chemotherapy cycles.Results:The difference in the scoring for the frequency and severity of nausea and vomiting in two groups was statistically significant(P <0.05).The scores of nurses’ cognition level of CINV were compared between before and after the interventions,and the difference had statistical significance(P <0.05).Conclusion:The management mode aiming to build vomit-free wards could decrease the incidence of CINV in patients during chemotherapy,and at the same time increased the cognitive level of nursing staff toward CINV,which is of great value in clinical practice and is worthy of further application.展开更多
在水热法合成LiFePO_(4)和HF刻蚀合成Mxene(金属碳/氮化物)的基础上,通过湿化学法制备了不同Mxene含量的Mxene/LiFePO_(4)复合正极材料,并对其物相、形貌和电化学性能进行了研究。结果表明,Mxene纳米片在LFP颗粒中的负载,使得LiFePO_(4)...在水热法合成LiFePO_(4)和HF刻蚀合成Mxene(金属碳/氮化物)的基础上,通过湿化学法制备了不同Mxene含量的Mxene/LiFePO_(4)复合正极材料,并对其物相、形貌和电化学性能进行了研究。结果表明,Mxene纳米片在LFP颗粒中的负载,使得LiFePO_(4)和Mxene之间通过“点到面”的导电模式在复合电极中构建高效导电网络,提高LiFePO_(4)正极材料的电子导电性。同时,Mxene二维层状结构的特点缩短了锂离子在正极材料中的扩散路径。因此,Mxene/LiFePO_(4)正极材料表现出良好的电化学性能,包括离子导电性和电子导电性等。其中,3%Mxene的负载,在0.1、1和5C充放电倍率下,首次放电比容量分别为159.3、136.8和100.2 m Ah·g^(-1),表现出良好的循环稳定性。展开更多
基金This study was sponsored by Novartis Pharma AG,Basel,Switzerland。
文摘Background:Psoriasis is a chronic inflammatory skin disease,affecting about 0.6%of the Chinese population.Many patients are not well controlled by conventional treatments,thus there is need for new treatment regimens.In this study,we assessed the efficacy and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis.Methods:This study was a 52-week,multicentre,randomized,double-blind,placebo-controlled,parallel-group,Phase 3 trial.A sub-population of study participants(≥18 years)of Chinese ethnicity were randomized to receive subcutaneous injections of 300 or 150 mg secukinumab,or placebo.The co-primary endpoints were psoriasis area severity index(PASI)75 and Investigator’s Global Assessment(IGA)0/1 at Week 12.Results:A total of 441 Chinese patients were enrolled in this study.Co-primary outcomes were achieved;300 and 150 mg secukinumab were superior to placebo as shown in the proportion of patients that achieved PASI 75(97.7%and 87.2%vs.3.7%,respectively;P<0.001),and IGA 0/1(82.3%and 69.7%vs.2.7%;P<0.001)at Week 12.Treatment efficacy was maintained until Week 52.There was no increase in overall adverse events with secukinumab relative to placebo throughout the 52-week period.Conclusion:Secukinumab is highly effective and well tolerated in Chinese patients with moderate to severe plaque psoriasis.
基金supported by the National Key Project (2009CB941601, 2008ZX08006-004 and 2009ZX0890-024B)the Joint Funds of the National Natural Science Foundation of China (u0731004)
文摘Background： o-galactosidase has been widely used in animal husbandry to reduce anti-nutritional factors （such as o-galactoside） in feed. Intestine-specific and substrate inducible expression of a-galactosidase would be highly beneficial for transgenic animal production. Methods： To achieve the intestine-specific and substrate inducible expression of o-galactosidase, we first identified intestine-specific promoters by comparing the transcriptional activity and tissue specificity of four intestine-specific promoters from human intestinal fatty acid binding protein, rat intestinal fatty acid binding protein, human mucin-2 and human lysozyme. We made two chimeric constructs combining the promoter and enhancer of human mucin-2, rat intestinal trefoil factor and human sucrase-isomaltase. Then a modified lac operon system was constructed to investigate the induction of o-galactosidase expression and enzyme activity by isopropyl p-D-]-thiogalactopyranoside （IPTG） and an a-galactosidase substrate, a-lactose. We declared that the research carried out on human （Zhai Yafeng） was in compliance with the Helsinki Declaration and experimental research on animals also followed internationally recognized guidelines. Results： The activity of the human mucin-2 promoter was about 2 to 3 times higher than that of other intestine-specific promoters. In the/ac operon system, the repressor significantly decreased （P 〈 0.05） luciferase activity by approximately 6.5-fold and reduced the percentage of cells expressing green fluorescent protein （GFP） by approximately 2-fold. In addition, the expression level of o-galactosidase mRNA was decreased by 6-fold and a-galactosidase activity was reduced by 8-fold. in line with our expectations, IPTG and a-lactose supplementation reversed （P 〈 O.O5） the inhibition and produced a 5-fold increase of luciferase activity, an 11-fold enhancement in the percentage of cells with GFP expression and an increase in o-galactosidase mfiNA abundance （by about 5-fold） and o-ga
基金project was supported by Southern Hospital of Southern Medical University(No.2016H006)
文摘Objective:To build a vomit-free ward of scientific and standardized management mode,and to evaluate its clinical effects on preventing nausea and vomiting in patients undergoing chemotherapy.Methods:A total of 200 patients suffering from nausea and vomiting were randomly selected from the registration system,from which 120 cases were enrolled according to the inclusion and exclusion criteria.These subjects were divided into control group and observation group(60 patients in each).Both of the two groups received routine nursing care,while the treatment group subjects lived in the vomit-free wards where extra nursing interventions were applied to prevent chemotherapy-induced nausea and vomiting(CINV),with constant observation of the frequency and severity of nausea and vomiting.The outcomes of the subjects from both the groups as well as nurses’ cognition level of CINV were compared after four chemotherapy cycles.Results:The difference in the scoring for the frequency and severity of nausea and vomiting in two groups was statistically significant(P <0.05).The scores of nurses’ cognition level of CINV were compared between before and after the interventions,and the difference had statistical significance(P <0.05).Conclusion:The management mode aiming to build vomit-free wards could decrease the incidence of CINV in patients during chemotherapy,and at the same time increased the cognitive level of nursing staff toward CINV,which is of great value in clinical practice and is worthy of further application.
文摘在水热法合成LiFePO_(4)和HF刻蚀合成Mxene(金属碳/氮化物)的基础上,通过湿化学法制备了不同Mxene含量的Mxene/LiFePO_(4)复合正极材料,并对其物相、形貌和电化学性能进行了研究。结果表明,Mxene纳米片在LFP颗粒中的负载,使得LiFePO_(4)和Mxene之间通过“点到面”的导电模式在复合电极中构建高效导电网络,提高LiFePO_(4)正极材料的电子导电性。同时,Mxene二维层状结构的特点缩短了锂离子在正极材料中的扩散路径。因此,Mxene/LiFePO_(4)正极材料表现出良好的电化学性能,包括离子导电性和电子导电性等。其中,3%Mxene的负载,在0.1、1和5C充放电倍率下,首次放电比容量分别为159.3、136.8和100.2 m Ah·g^(-1),表现出良好的循环稳定性。
